Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 268 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Part 1 and 2 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

NCT01511432
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
telaprevir formulation A, telaprevir Formulation B, telaprevir Formulation C, telaprevir Formulation D
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 4, 2012 · Synced Oct 22, 2026, 8:08 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

NCT04440735
View directory record Official record
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
Interventions
DSP107, Atezolizumab
Biological
Lead sponsor
Kahr Medical
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
La Jolla, California • Aurora, Colorado • Lake Mary, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 22, 2026, 8:08 PM EDT
Terminated Phase 1Phase 2 Interventional

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

NCT03283826
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
ATA188, Placebo
Biological · Drug
Lead sponsor
Atara Biotherapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 22, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients

NCT01795339
View directory record Official record
Conditions
Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients
Interventions
AZD3293, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Oct 22, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

NCT05720767
View directory record Official record
Conditions
Relapsed or Refractory Lymphoma
Interventions
HMPL-523, Itraconazole, Rifampin
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 22, 2026, 8:08 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects

NCT05997641
View directory record Official record
Conditions
Healthy, Safety and Tolerability
Interventions
DF-003, Placebo
Drug
Lead sponsor
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 22, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine

NCT05418582
View directory record Official record
Conditions
Healthy Subjects
Interventions
DZD9008 and intraconazole, DZD9008 and carbamazepine
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 22, 2026, 8:08 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

NCT06597006
View directory record Official record
Conditions
Familial Hypercholesterolemia - Homozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 22, 2026, 8:08 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Carbamazepine or Itraconazole on Radiprodil in Healthy Adult Participants

NCT07884734
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
Radiprodil, Carbamazepine, Itraconazole (200 mg)
Drug
Lead sponsor
GRIN Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 8:08 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT326, Pumitamig, Itraconazole, Paroxetine
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
19
States / cities
Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 8:08 PM EDT
Not listed Phase 2 Interventional

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

NCT05747508
View directory record Official record
Conditions
Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
INOpulse®, Placebo, Long Term Follow Up
Combination Product
Lead sponsor
Bellerophon
Industry
Eligibility
18 Years to 85 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 22, 2026, 8:08 PM EDT
Terminated Phase 3 Interventional Results available

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)

NCT02134015
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
Patritumab, Erlotinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
20 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Glendale, Arizona • Duarte, California • La Verne, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 22, 2026, 8:08 PM EDT
Completed Phase 1Phase 2 Interventional

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

NCT06664502
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
Interventions
EYE201
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Scottsdale, Arizona • Modesto, California • Mountain View, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 22, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants

NCT05134337
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LOXO-305, Itraconazole, Rifampin
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 22, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

NCT01733875
View directory record Official record
Conditions
Healthy
Interventions
CC-220 0.03 mg, CC-220 0.1 mg, CC-220 0.3 mg, CC-220 1 mg, CC-220 2 mg, Placebo, CC-220
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 22, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess PDM608 in Healthy Adult Subjects

NCT05950906
View directory record Official record
Conditions
Parkinson Disease
Interventions
PDM608, Placebo
Drug
Lead sponsor
Calibr, a division of Scripps Research
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 22, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Results available

A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors

NCT01457417
View directory record Official record
Conditions
Multiple Myeloma, Solid Tumors, Non-Small Cell Lung Cancer
Interventions
DKN-01
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
30 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Scottsdale, Arizona • Albany, New York • Greenville, South Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 22, 2026, 8:08 PM EDT
Completed Phase 1 Interventional

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

NCT03309111
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
ISB 1342
Biological
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
9
States / cities
Denver, Colorado • Baltimore, Maryland • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 22, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study of Rapid Haplotyping Procedure for Personalized Dosing of Dichloroacetate (DCA) in Healthy Volunteers

NCT02690285
View directory record Official record
Conditions
Healthy
Interventions
Dichloroacetate (DCA), GSTZ1 haplotyping
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 22, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Results available

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia

NCT01440374
View directory record Official record
Conditions
Thrombocytopaenia
Interventions
eltrombopag, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 110 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
18
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Jonesboro, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 22, 2026, 8:08 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

NCT07314346
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Hollywood, Florida • Overland Park, Kansas • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 22, 2026, 8:08 PM EDT
Not listed Phase 1 Interventional

Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors

NCT03398720
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
HTI-1066 dose level 1, HTI-1066 dose level 2, HTI-1066 dose level 3, HTI-1066 dose level 4
Drug
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Scottsdale, Arizona • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 22, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of HU6

NCT06486558
View directory record Official record
Conditions
Healthy
Interventions
HU6 450 mg Tablet, HU6 150 mg Capsules x 3 (Total dose = 450 mg)
Drug
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 22, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fruquintinib CYP3A Inhibitor and Inducer Study

NCT04557397
View directory record Official record
Conditions
Drug Drug Interaction
Interventions
Fruquintinib, Itraconazole, Rifampin
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 22, 2026, 8:08 PM EDT